Mostrar el registro sencillo del ítem

Increased lipoprotein(a) in a paediatric patient associated with nephrotic syndrome [Incremento de lipoproteína(a) en paciente pediátrico asociado a síndrome nefrótico]

dc.contributor.authorMenéndez Valladares P.
dc.contributor.authorArrobas Velilla T.
dc.contributor.authorBermúdez de la Vega J.A.
dc.contributor.authorRomero Pérez M.D.M.
dc.contributor.authorFabiani Romero F.
dc.contributor.authorGonzález Rodríguez C.
dc.date.accessioned2020-09-02T22:22:57Z
dc.date.available2020-09-02T22:22:57Z
dc.date.issued2016
dc.identifier10.1016/j.arteri.2016.06.006
dc.identifier.citation28, 5, 227-229
dc.identifier.issn02149168
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5311
dc.descriptionA common complication in paediatric patients with nephrotic syndrome (NS) is hyperlipidaemia. About 20% of children do not respond to treatment with corticosteroids, presenting with a cortico-resistant NS (CRNS), which can progress to kidney failure. It has been observed that paediatric patients with CRNS have an elevated low density lipoprotein cholesterol (LDL-c), very low density lipoprotein cholesterol (VLDL-c), and triglycerides levels, as well as elevated Lipoprotein-a [Lp (a)] levels. The case is presented of a 5 year old boy, diagnosed with CRNS, presenting with dyslipidaemia with increased LDL-c, Apo-B100, and Lp(a) levels. After the poor prognosis of the renal function, immunosuppressant treatment was started with tacrolimus and atorvastatin to control dyslipidaemia. Although tacrolimus causes an elevation of total cholesterol and LDL-c, the significant alterations of the children lipid profile suggest the existence of a high cardiovascular risk. In these cases, it would be interesting to have reference values in children in our health area. © 2016 Sociedad Española de Arteriosclerosis
dc.language.isoen
dc.language.isoes
dc.publisherElsevier Doyma
dc.subjectLDL-cholesterol
dc.subjectLipoprotein(a)
dc.subjectNephrotic syndrome
dc.subjectPaediatrics
dc.subjectapolipoprotein B100
dc.subjectatorvastatin
dc.subjectlipoprotein A
dc.subjectlow density lipoprotein cholesterol
dc.subjecttacrolimus
dc.subjecttriacylglycerol
dc.subjectapolipoprotein B100
dc.subjectimmunosuppressive agent
dc.subjectlipoprotein A
dc.subjectlow density lipoprotein cholesterol
dc.subjectArticle
dc.subjectcardiovascular risk
dc.subjectcase report
dc.subjectcausal attribution
dc.subjectchild
dc.subjectcholesterol blood level
dc.subjectdrug effect
dc.subjectdyslipidemia
dc.subjecthuman
dc.subjectlipoprotein blood level
dc.subjectmale
dc.subjectnephrotic syndrome
dc.subjectpreschool child
dc.subjecttriacylglycerol blood level
dc.subjectblood
dc.subjectcomplication
dc.subjectDyslipidemias
dc.subjectnephrotic syndrome
dc.subjectpathophysiology
dc.subjectprognosis
dc.subjectrisk factor
dc.subjectApolipoprotein B-100
dc.subjectAtorvastatin Calcium
dc.subjectChild, Preschool
dc.subjectCholesterol, LDL
dc.subjectDyslipidemias
dc.subjectHumans
dc.subjectImmunosuppressive Agents
dc.subjectLipoprotein(a)
dc.subjectMale
dc.subjectNephrotic Syndrome
dc.subjectPrognosis
dc.subjectRisk Factors
dc.subjectTacrolimus
dc.titleIncreased lipoprotein(a) in a paediatric patient associated with nephrotic syndrome [Incremento de lipoproteína(a) en paciente pediátrico asociado a síndrome nefrótico]
dc.typeArticle


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-84991232069.pdf
Tamaño:
3.416Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem